Skip to main content
Premium Trial:

Request an Annual Quote

Vimal Mehta, Nasri Nahas, Gregory Phelps

Premium

London-based Inpharmatica has tapped Vimal Mehta as its new senior VP of business development. Previously, Mehta served as senior business development manager at CuraGen, a position he held since 1996. At Inpharmatica, Mehta will lead commercialization efforts for the company’s discovery activities.

Nasri Nahas has been promoted from COO to CEO at Geneva Bioinformatics. Nahas will be charged with launching new products during 2003 and establishing new business operations and partnerships, GeneBio said in a statement. Previously, Nahas held scientific and business positions at Genset and ValiGen.

Ardais of Lexington, Mass., has hired Gregory Phelps as its CEO. Phelps has held executive positions at Baxter Travenol Laboratories, Dyax, and Genzyme. In his most recent position as vice chairman of Dyax, where he will retain his position as director, Phelps executed more than 70 patent and technology licenses and positioned the company for its IPO in 2000.

 

Filed under

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.